Xencor (XNCR) Price & Analysis

Compare

348 Followers

XNCR Stock Chart & Stats

$14.19

-$0.21(-0.88%)

At close: Jan 08 4:00 PM EST

$14.19

-$0.21(-0.88%)

Day’s Range― - ―

52-Week Range$6.92 - $21.00

Previous CloseN/A

Volume126.93K

Average Volume (3M)718.91K

Market Cap

$1.01B

Enterprise Value$0.00

Total Cash (Recent Filing)$471.04M

Total Debt (Recent Filing)$202.41M

Price to Earnings (P/E)―

Beta1.65

Next Earnings

Mar 04, 2026

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding71,410,470

10 Day Avg. Volume669,078

30 Day Avg. Volume718,909

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)2.21

Price to Sales (P/S)13.53

P/FCF Ratio-7.18

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$27.50

Price Target Upside93.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyInitial Phase I data demonstrated meaningful tumor responses and durable shrinkage in clear cell renal cell carcinoma, supporting clinical proof of concept for the lead T-cell engager and suggesting real patient benefit in a heavily pretreated population.

Dosing And Safety ManagementSite retraining and introduction of a low‑concentration formulation aim to eliminate manual dilution steps, which should reduce preparation errors and improve the safety profile by lowering severe cytokine release events.

Pipeline Breadth And Financial RunwayA diversified oncology and autoimmune pipeline combined with adequate capital position allows advancement of multiple programs toward pivotal studies, creating potential for significant value inflection if late‑stage readouts are positive.

Bears Say

Xencor News

Xencor price target raised to $20 from $17 at BofA

BofA raised the firm’s price target on Xencor (XNCR) to $20 from $17 and keeps a Neutral rating...

5d ago

XNCR

Xencor price target raised to $26 from $23 at Barclays

Barclays raised the firm’s price target on Xencor (XNCR) to $26 from $23 and keeps an Overweight rating...

25d ago

XNCR

Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases

Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Study Overview: Xencor Inc. has launched a...

26d ago

XNCR

Xencor issued U.S. patent for Xtend Fc domain

Xencor (XNCR) announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend Fc domain for extending the...

1M ago

XNCR

Xencor initiated with a Buy at Truist

Truist initiated coverage of Xencor (XNCR) with a Buy rating and $29 price target Lead program, TL1A, has...

2M ago

XNCR

Xencor’s Promising Oncology and Autoimmune Advances Justify Buy Rating with $38 Price Target

Canaccord Genuity analyst John Newman has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday....

2M ago

XNCR

Xencor price target raised to $42 from $40 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Xencor (XNCR) to $42 from $40 and keeps an Overweight...

2M ago

XNCR

Xencor price target lowered to $18 from $20 at JPMorgan

JPMorgan lowered the firm’s price target on Xencor (XNCR) to $18 from $20 and keeps an Overweight rating...

2M ago

XNCR

Xencor Reports Improved Q3 2025 Financial Results

Xencor Inc. ( ($XNCR) ) has released its Q3 earnings. Here is a breakdown of the information Xencor...

2M ago

XNCR

Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday....

2M ago

XNCR

Promising Developments in Xencor’s Oncology and Autoimmune Pipelines Justify Buy Rating

TD Cowen analyst Tara Bancroft has maintained their bullish stance on XNCR stock, giving a Buy rating on...

2M ago

XNCR

Xencor reports Q3 EPS (8c), consensus (70c)

Reports Q3 revenue $21.0M, consensus $28.7M. “Xencor’s (XNCR) two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and...

2M ago

XNCR

Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner

The stock markets have been ripping this year, with investors buying into the bullish trend. However, some savvy...

2M ago

GKOS

XNCR

Xencor upgraded to Overweight from Underweight at Barclays

Barclays analyst Etzer Darout double upgraded Xencor (XNCR) to Overweight from Underweight with a price target of $23,...

2M ago

XNCR

XNCR FAQ

What was Xencor Inc’s price range in the past 12 months?

Xencor Inc lowest stock price was $6.92 and its highest was $21.00 in the past 12 months.

What is Xencor Inc’s market cap?

Xencor Inc’s market cap is $1.01B.

When is Xencor Inc’s upcoming earnings report date?

Xencor Inc’s upcoming earnings report date is Mar 04, 2026 which is in 52 days.

How were Xencor Inc’s earnings last quarter?

Xencor Inc released its earnings results on Nov 05, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.689 by $0.609.

Is Xencor Inc overvalued?

According to Wall Street analysts Xencor Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xencor Inc pay dividends?

Xencor Inc does not currently pay dividends.

What is Xencor Inc’s EPS estimate?

Xencor Inc’s EPS estimate is -0.6.

How many shares outstanding does Xencor Inc have?

Xencor Inc has 71,410,470 shares outstanding.

What happened to Xencor Inc’s price movement after its last earnings report?

Xencor Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.689. Following the earnings report the stock price went down -2.575%.

Which hedge fund is a major shareholder of Xencor Inc?

Currently, no hedge funds are holding shares in XNCR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Xencor Stock Smart Score

Neutral

Fundamentals

Return on Equity

-19.61%

Trailing 12-Months

Asset Growth

-13.11%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xencor Inc

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Xencor (XNCR) Earnings & Revenues

Historic Earnings Reports

XNCR Stock 12 Month Forecast

Average Price Target

$27.50

▲(93.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","43":"$43","15.25":"$15.25","24.5":"$24.5","33.75":"$33.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,15.25,24.5,33.75,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.31,17.363076923076925,19.416153846153847,21.46923076923077,23.52230769230769,25.575384615384614,27.628461538461536,29.68153846153846,31.73461538461538,33.7876923076923,35.840769230769226,37.89384615384615,39.94692307692308,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.31,16.247692307692308,17.185384615384617,18.123076923076923,19.060769230769232,19.998461538461537,20.936153846153847,21.873846153846152,22.81153846153846,23.74923076923077,24.686923076923076,25.62461538461538,26.56230769230769,{"y":27.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.31,15.516923076923078,15.723846153846154,15.930769230769231,16.13769230769231,16.344615384615384,16.551538461538463,16.75846153846154,16.965384615384615,17.172307692307694,17.37923076923077,17.586153846153845,17.793076923076924,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >